COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • May 5th, 2020 • Incyte Corp • Services-commercial physical & biological research
Contract Type FiledMay 5th, 2020 Company IndustryZur Vorlage beim Amtsgericht München – Handelsregister – bestätigen wir hiermit hinsichtlich der von dem Vorstand der Gesellschaft am [•] 2020 mit Zustimmung des Aufsichtsrats vom [•] 2020 beschlossenen Kapitalerhöhung über insgesamt € [•], dass wir heute der
AMENDMENT NO. 5 TOCollaboration and License Agreement • May 5th, 2020 • Incyte Corp • Services-commercial physical & biological research
Contract Type FiledMay 5th, 2020 Company IndustryTHIS AMENDMENT NO. 5 TO COLLABORATION AND LICENSE AGREEMENT (this “Amendment No. 5”) is entered into as of the 20th day of March, 2020 (the “Effective Date”), by and between Incyte Corporation, a Delaware corporation having an office at 1801 Augustine Cut-Off, Wilmington, Delaware (“Incyte”), and Novartis International Pharmaceutical AG, a company limited by shares organized under the laws of Switzerland having an office at Lichtstrasse 35, 4056 Basel, Switzerland (“Novartis”).